Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.70    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.30 (19.355%)
Market Cap: £264.88k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Restructuring Update

2 Feb 2023 07:55

RNS Number : 7169O
Iconic Labs PLC
02 February 2023
 

Iconic Labs PLC

 

("Iconic" or the "Company")

 

Restructuring Update

 

 

Iconic Labs PLC (LSE:ICON), provides this restructuring update following this first week after the trading suspension was lifted.

 

Iconic thanks its shareholders for their patience as management continues to stabilise the Company. Lifting the trading suspension was a significant step forward for the Company and whilst the Directors understand that shareholders are eager for news about the future, potential acquisitions, and strategy, their current focus is necessarily on completing the restructuring process.

Firstly, to fulfill its obligations under the Company Voluntary Arrangement ("CVA"), Iconic still must make two cash payments of £50,000 each for the months of February and March, and then a final £15,000 payment for April.

The cash for these payments shall come from the £3 million financing facility with European High Growth Opportunities Securitization Fund ("EHGOSF") provided (i) the closing market price of the shares for each of the ten consecutive trading days falling immediately prior to the relevant closing date is at least higher than 150% of the nominal value of Iconic's shares; and (ii) the average daily value traded of Iconic's shares (excluding 5% of the data points from the top and excluding 5% of the data points from the bottom of the data set) for the 20 trading days immediately prior to the applicable closing date is at least £ 10,000.

EHGOSF provides this financing to Iconic through notes with warrants attached that are then converted into shares. While this leads to some dilution, the Company asks that shareholders recognise that this financing does not lead to any corresponding cash liability; meaning, Iconic does not owe cash to EHSOSF for this financing. This is a valuable financing tool for a company in Iconic's position striving to have clean books with no liabilities.

Secondly, once those three payments have been made, Iconic must then fulfill its final obligation under the CVA of issuing 1,674,130,609 shares to the unsecured creditors. Iconic reminds shareholders that again, whilst this will lead to some dilution, these unsecured creditors had cash claims against the Company. Those claims have been cleared from Iconic's books and satisfied with a 75% discount paid in shares.

Thirdly, secured creditor claims brought against Iconic of roughly £4,200,000 were reduced to £750,000 to be satisfied through the issue of convertible notes, and EHGOSF reduced its historic claims against Iconic of £3,000,000 down to £750,000 to be satisfied through the issue of convertible notes. Again, this will result in some dilution, but compared to the original sums claimed against the Company, this is a significant result.

Finally, regarding potential acquisitions, Iconic has been in early stage talks with various parties. However, given that the trading suspension was only lifted last week, Iconic is only now able to move beyond preliminary discussions with those parties. It is anticipated that any acquisition that Iconic makes will most likely be a reverse takeover under the Listing Rules. Further updates on these discussions will be provided in due course.

Brad Taylor, CEO stated:

"Restructuring a company that was in the distressed position that Iconic was in is a lengthy process. We have succeeded in exiting administration and getting the trading suspension lifted, two accomplishments that have rarely, if ever, been done before for a main market LSE company. We continue the process of stabilising the Company and discussing potential acquisitions with various entities so that we can generate shareholder value."

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

For any further information or enquiries please contact:

 

ir@iconiclabs.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDLLBBXLLEBBL
Date   Source Headline
30th Oct 20184:25 pmRNSNotice of AGM
30th Oct 20182:05 pmRNSSecond Price Monitoring Extn
30th Oct 20182:00 pmRNSPrice Monitoring Extension
30th Oct 20187:00 amRNSWideacademy Restructuring
29th Oct 20184:33 pmRNSHolding(s) in Company
23rd Oct 20188:27 amRNSConversion of Bond
22nd Oct 20183:27 pmRNSConversion of bonds
22nd Oct 20187:00 amRNSSmart Cells Deal
19th Oct 20189:20 amRNSHolding(s) in Company
18th Oct 201812:47 pmRNSBoard Restructuring
17th Oct 20184:48 pmRNSHolding(s) in Company
1st Oct 201811:00 amRNSPrice Monitoring Extension
28th Sep 20183:30 pmRNSHolding(s) in Company
27th Sep 20184:40 pmRNSSecond Price Monitoring Extn
27th Sep 20184:35 pmRNSPrice Monitoring Extension
27th Sep 201810:40 amRNSNotification of transactions of Directors
27th Sep 20187:10 amRNSInterim Results
27th Sep 20187:00 amRNSFinancing Agreement
30th Jul 20187:00 amRNSCellPlan Launch in Spain
9th Jul 20187:01 amRNSBoard Changes
9th Jul 20187:00 amRNSHolding(s) in Company
29th Jun 20183:00 pmRNSResult of AGM
28th Jun 201810:30 amRNSResult of General Meeting
15th Jun 20187:00 amRNSAlign Research Initiation of Coverage
12th Jun 20186:25 pmRNSProspectus and Notice of General Meeting
11th Jun 20189:00 amRNSLive Market Bookbuild Closes
11th Jun 20187:30 amRNSRestoration Widecells Group Plc
11th Jun 20187:00 amRNSUpdate Regarding Placing and Financial Position
6th Jun 20183:00 pmRNSNotice of AGM
5th Jun 20187:00 amRNSAudited Preliminary Results
21st May 20187:00 amRNSFinal Results Update
10th May 201810:30 amRNSPlacing to Raise £1.47m and Live Market Bookbuild
3rd May 20187:30 amRNSSuspension Widecells Group
1st May 20187:02 amRNSAnnual Accounts and Fundraising Update
26th Mar 20187:00 amRNSLandmark deal to launch CellPlan insurance in Asia
19th Mar 20187:00 amRNSGranted Innovate UK KTP for Stem Cell Research
27th Feb 20187:00 amRNSLicence Award from the Human Tissue Authority
19th Feb 20187:00 amRNSBoard Changes and Launch of Wideacademy Platform
21st Dec 20177:00 amRNSCorporate Update
2nd Nov 20177:00 amRNSRevenue generation with White Apex agreement
12th Oct 20177:00 amRNSCellPlan expansion, e-commerce platform launch UK
11th Oct 20177:00 amRNSPartner Secured to Expand into MENA & Asia-Pacific
29th Sep 20177:00 amRNSInterim Results
25th Sep 20177:00 amRNSWideacademy Update, Presenting at Investor Event
15th Aug 20177:00 amRNSRaises £750,000 to support Company's divisions
31st Jul 20177:00 amRNSResearch Licence Granted from HTA
24th Jul 20177:00 amRNSNew product to target the dental market
21st Jul 20177:00 amRNSCellPlan launches E-Commerce Platform in the UK
12th Jul 20177:00 amRNSCorporate Charity Commitment
4th Jul 20177:00 amRNSAgreement to Roll Out CellPlan in Brazil

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.